Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III prophylaxis study of human coagulation factor IX in treated adolescents and adults with hemophilia B
CTR20262015Phase 3Active
- Sponsor
- Shandong Taibang Biological Products
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human coagulation factor IX in hemophilia B (HB), sponsored by Shandong Taibang Biological Products. Started Jul 2026; status: active.
02
Drugs
human coagulation factor IX
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20262015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262015.